Press Release
January 19, 2024
iPark Institute Co., Ltd.

iPark Institute Signs Memorandum of Understanding(MOU) on Mutual Cooperation in the Bio-Healthcare
Field with Osong Medical Innovation Foundation(KBIOHealth) in Korea⚫

Collaboration between Japan-Korea innovation hubs in the field ofbiotechnology and healthcare will bring innovation from Asia to the world⚫

iPark Institute Co., Ltd. is strengthening collaboration between Shonan
Health Innovation Park (Shonan iPark) and innovation hubs in Asia, and ispromoting collaboration with innovation hubs in South Korea in terms oftechnology, human resources, and information

iPark Institute Co., Ltd. (Headquarters: Fujisawa City, Kanagawa Prefecture; CEO: Toshio
Fujimoto; hereinafter referred to as "iPark Institute") announced on January 19 thatOsong Medical Innovation Foundation (hereinafter referred to as “KBIOHealth”), a public
institution in South Korea (Headquarters: Cheongju City, North Chungcheong Province;
Chairman & CEO: Sang-hoon Cha) and iPark Institute have signed a memorandum ofunderstanding (MOU) with the aim of collaboration in the fields of bio-healthcare.
According to the MOU, iPark Institute and KBIOHealth (hereinafter referred to as the "twoorganizations"), both of whom are in a position to support life science companies in Japanand South Korea respectively, will cooperate in (1) exchanging experts throughdispatches, (2) establishing an external liaison office, (3) participating in internalseminars, and (4) giving priority invitations to special seminars and speakerprivileges.
Based on the mission of "build a life science ecosystem that is open to the world", iPark
Institute has signed memorandums of understanding (MOUs) with science parks in Japanand overseas. This is the eighth such partnership, and follows the partnership enteredinto with the Korean Ministry of SMEs and Startups in November 2023.

From left to right: Toshio Fujimoto, CEO of iPark Institute, and Sang-hoon Cha, Chairman and CEO ofKBIOHealth

Regarding this business agreement, Sang-hoon Cha, the Chairman & CEO of KBIOHealth,said:"KBIOHealth is a nationally-led CRDMO institution equipped with ‘The best service withworld-class technology for the customers.’ Through this agreement, we anticipate thatexchanging exceptional development technologies between the two countries will
accelerate the introduction of superior biological drugs to the world."
In addition, Toshio Fujimoto, CEO of iPark Institute, said:"Since its inception, Shonan iPark has made it its mission to build a life science ecosystemthat is open to the world. Japan and South Korea each have their own issues to overcome
in order to develop and commercialize excellent technologies. If the two institutions canwork together to reinforce each other's challenges and build a regional ecosystem thattranscends national boundaries, we believe that it will be a source of new innovation thatwill spread the eminent technologies of both countries to the world."
About Osong Medical Innovation Foundation (KBIOHealth)
The Osong Medical Innovation Foundation (KBIOHealth) is a government-led organization
under the Ministry of Health and Welfare, established to nurture the bio-health industry
as a future national growth engine. In November 2013, the foundation completed theconstruction of four core facilities, including the New Drug Development Center, MedicalDevice Development Center, Non-clinical Evaluation Center, and BioPharmaceutical
Manufacturing Center. Each center is equipped with highly advanced facilities andequipment to support the development of bio drugs and BT-based medical devices.
KBIOHealth serves as a “Research and Development Service Platform” aimed at fostering
the growth of advanced medical industries through the activation and dissemination ofresearch in the fields of bio drugs and BT-based medical devices. It fills the void where
the private sector may fall short, providing services needed by the government. Thefoundation plays a pivotal role in accelerating the commercialization and industrializationof advanced pharmaceuticals and medical device products. Beyond supporting applied
development research, KBIOHealth also offers consulting on research directions forbusiness development. Recognizing that even projects with the potential for successfulcommercialization often face obstacles in the early stages or encounter challenges lateron, the foundation, as a national infrastructure, corrects these directions and guides themthrough to the commercialization stage.
Homepage: https://www.kbiohealth.kr/en/
Social media: YouTube / Facebook / Instagram / Blog
About iPark Institute Co., Ltd.
iPark Institute Co., Ltd. was established in 2023 with Industrial & Infrastructure Fund
Investment Corporation (IIF), Takeda Pharmaceutical Company Limited (Takeda) andMitsubishi Corporation as major shareholders. It took over the management of Shonan
Health Innovation Park (Fujisawa City, Kanagawa Prefecture) in 2023, which Takeda had
been responsible for since 2018.
In addition to the operation and management of the facilities, the company is engaged
in projects to build and revitalize the life science ecosystem, including the promotion ofinnovation creation, technology exchange, and research collaboration. Find out more
about our company here.
About Shonan Health Innovation Park (Shonan iPark)
Shonan Health Innovation Park (Shonan iPark) is Japan's first pharmaceutical-initiatedscience park, established in April 2018 when Takeda Pharmaceutical Company Limited(Takeda) opened its then in-house research center to outside organizations. It is now
operated by iPark Institute Co., Ltd., and aims to become a place where industry,government, and academia from a wide range of industries and sizes can come together
to accelerate health innovation. Shonan iPark is currently home to about 170 companies
and more than 2,000 people (as of January 2024) from not only pharmaceuticalcompanies but also next-generation medicine, cell agriculture, AI, government, and otherfields, forming an ecosystem.
Homepage: https://www.shonan-ipark.com/en/?utm_source=media-pressrelease
Tenant Overview: https://www.shonan-ipark.com/en/membership/list/

Social media: YouTube / Facebook / Twitter / LinkedIn
For inquiries regarding this matter, please contact:
iPark Institute Co., Ltd. Communication
Mail：iPi.Com@shonan-ipark.com